Disease · MONDO_0002108
Trials115
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 115
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01876784 | Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer | Phase 3 | 238 | 2017-03-13 | Differentiated Thyroid Cancer | VANDETANIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01843062 | Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer | Phase 3 | 233 | 2019-04-22 | Differentiated Thyroid Cancer | SELUMETINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | Phase 3 | 187 | 2023-05-18 | Differentiated Thyroid Cancer | CABOZANTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | Phase 2 | 93 | 2025-06-19 | Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma | ATEZOLIZUMAB, CABOZANTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | Phase 2 | 63 | 2024-07-11 | Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor | TIPIFARNIB | Its record names the disease | ClinicalTrials.gov |
| NCT00094055 | Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer | Phase 2 | 60 | 2012-03-30 | Thyroid Neoplasms | AXITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02393690 | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | Phase 2 | 60 | 2021-08-03 | Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 | SELUMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | Phase 2 | 59 | 2019-11-18 | Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer | SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | Phase 2 | 53 | 2025-08-24 | Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00389441 | Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | Phase 2 | 52 | 2013-11-25 | Thyroid Neoplasms | AXITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00936858 | RAD001 for Patients With Radioiodine Refractory Thyroid Cancer | Phase 2 | 50 | 2021-09-28 | Thyroid Cancer | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | Phase 1/2 | 46 | 2024-01-12 | Anaplastic Thyroid Cancer, Thyroid Cancer, Differentiated Thyroid Cancer | SAPANISERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | Phase 2 | 41 | 2017-03-15 | Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01025453 | Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer | Phase 2 | 37 | 2018-08-15 | Thyroid Cancer | SORAFENIB, TEMSIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | Phase 2 | 35 | 2017-04-25 | Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma | SUNITINIB MALATE | Its record names the disease | ClinicalTrials.gov |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | Phase 2 | 34 | 2022-12-28 | Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 | TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00095836 | Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy | Phase 2 | 27 | 2017-05-31 | Head and Neck Cancer | GEFITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | Phase 1/2 | 27 | 2015-12-31 | Solid Tumor, Anaplastic Thyroid Cancer | CISPLATIN, CROLIBULIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01882816 | Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer | Phase 2 | 27 | 2022-12-29 | Thyroid Cancer | DOXORUBICIN | Its record names the disease | ClinicalTrials.gov |
| NCT00970359 | Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 | Not applicable | 24 | 2017-04-12 | Thyroid Cancer | SELUMETINIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002108/trials